SI0958821T1 - Fat emulsion containing xanthine derivative - Google Patents

Fat emulsion containing xanthine derivative

Info

Publication number
SI0958821T1
SI0958821T1 SI9730675T SI9730675T SI0958821T1 SI 0958821 T1 SI0958821 T1 SI 0958821T1 SI 9730675 T SI9730675 T SI 9730675T SI 9730675 T SI9730675 T SI 9730675T SI 0958821 T1 SI0958821 T1 SI 0958821T1
Authority
SI
Slovenia
Prior art keywords
fat emulsion
xanthine derivative
emulsion containing
containing xanthine
hydroxyl
Prior art date
Application number
SI9730675T
Other languages
English (en)
Slovenian (sl)
Inventor
Toshihito Hosokawa
Kenji Iwata
Yuji Kawaguchi
Yasuki Kato
Kunio Ito
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Publication of SI0958821T1 publication Critical patent/SI0958821T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Edible Oils And Fats (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9730675T 1996-08-07 1997-08-07 Fat emulsion containing xanthine derivative SI0958821T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP22439996 1996-08-07
PCT/JP1997/002773 WO1998005334A1 (en) 1996-08-07 1997-08-07 Fat emulsion containing xanthine derivative
EP97934737A EP0958821B1 (en) 1996-08-07 1997-08-07 Fat emulsion containing xanthine derivative

Publications (1)

Publication Number Publication Date
SI0958821T1 true SI0958821T1 (en) 2005-02-28

Family

ID=16813150

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730675T SI0958821T1 (en) 1996-08-07 1997-08-07 Fat emulsion containing xanthine derivative

Country Status (15)

Country Link
US (1) US6210687B1 (xx)
EP (1) EP0958821B1 (xx)
JP (2) JP4179631B2 (xx)
KR (1) KR20000029672A (xx)
CN (1) CN1227490A (xx)
AT (1) ATE281835T1 (xx)
AU (1) AU3784597A (xx)
CA (1) CA2262578A1 (xx)
DE (1) DE69731556T2 (xx)
DK (1) DK0958821T3 (xx)
ES (1) ES2232877T3 (xx)
NZ (1) NZ334299A (xx)
PT (1) PT958821E (xx)
SI (1) SI0958821T1 (xx)
WO (1) WO1998005334A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123538A1 (en) * 2000-12-29 2002-09-05 Peiguang Zhou Hot-melt adhesive based on blend of amorphous and crystalline polymers for multilayer bonding
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
KR20060004959A (ko) * 2003-04-25 2006-01-16 노바카르디아, 인코포레이션 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
EP1932529A1 (en) 2003-04-25 2008-06-18 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
EP1755594A1 (en) * 2004-04-16 2007-02-28 Novacardia, Inc. Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
CN101166515A (zh) * 2005-04-22 2008-04-23 美国诺华卡迪亚公司 用于非水溶性药物成分静脉注射的乳剂的生产
US7893070B2 (en) 2005-08-15 2011-02-22 Provimi Holding B.V. Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
AR057755A1 (es) * 2005-08-15 2007-12-19 Provimi Holding B V Metodo para tratar mamiferos placentarios parturientos con el fin de reducir el agotamiento materno y/o uterino
EP1961422A1 (en) * 2005-12-14 2008-08-27 Kyowa Hakko Kogyo Co., Ltd. Easily absorbed oral preparation containing xanthine derivative
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
BR112013008601B1 (pt) 2010-10-12 2020-03-31 Chiesi Farmaceutici S.P.A. Formulações de emulsão de clevidipina contendo agentes antimicrobianos
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
JP7331417B2 (ja) 2019-03-29 2023-08-23 セイコーエプソン株式会社 メディア支持構造及び記録装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146621A (en) * 1973-01-16 1979-03-27 The Regents Of The University Of Michigan Process of treating proliferative skin diseases
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JPH07285863A (ja) * 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
JPH0881360A (ja) * 1994-07-13 1996-03-26 Wakamoto Pharmaceut Co Ltd 安定な脂肪乳剤
JP4008965B2 (ja) * 1994-07-29 2007-11-14 昭和産業株式会社 レシチン含有脂肪乳剤の調製法
JPH08104620A (ja) * 1994-10-05 1996-04-23 Green Cross Corp:The 薬物含有脂肪乳剤

Also Published As

Publication number Publication date
PT958821E (pt) 2005-02-28
DK0958821T3 (da) 2005-01-03
ATE281835T1 (de) 2004-11-15
US6210687B1 (en) 2001-04-03
EP0958821A4 (en) 2003-05-02
DE69731556T2 (de) 2005-10-27
JP4179631B2 (ja) 2008-11-12
DE69731556D1 (de) 2004-12-16
ES2232877T3 (es) 2005-06-01
AU3784597A (en) 1998-02-25
EP0958821A1 (en) 1999-11-24
JP2008231117A (ja) 2008-10-02
WO1998005334A1 (en) 1998-02-12
NZ334299A (en) 1999-05-28
KR20000029672A (ko) 2000-05-25
CN1227490A (zh) 1999-09-01
EP0958821B1 (en) 2004-11-10
CA2262578A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
EP0784974A4 (en) SOLID DISPERSION OR SOLID DISPERSION PREPARATION OF XANTHINE DERIVATIVES
NZ334299A (en) Fat emulsion containing xanthine derivative
EP0705833A4 (en) DC-89 DERIVATIVES
SG44794A1 (en) Novel peptide derivatives
AU9281198A (en) Benzofuran derivatives
NZ330775A (en) 7-isoindolinyl-quinolonecarboxylic acid derivatives or salts thereof
HUT73437A (en) Novel pyrrolocarbazoles
EP1454903A4 (en) THIADIAZOLINDERIVAT
IL130484A0 (en) 16-ENE-vitamin D derivatives
HK1031867A1 (en) 2-phenoxyaniline derivatives
CA2092919A1 (en) Epoxysuccinamic acid derivatives
TW288012B (xx)
EP0230474A4 (en) BIS-DIOXOPIPERAZINE COMBATS AND MEDICINAL PRODUCTS THEREOF.
EP0573659A4 (en) Pyrazolothiazolopyrimidine derivative
KR890009887A (ko) 이미다졸 유도체
GB2190587B (en) Prophylactic and curing composition for arteriosclerosis
EP0278008A4 (en) TAURINE TYPE COMPOUNDS.
EP0614897A4 (en) IMIDAZONAPHTYRIDINE DERIVATIVE.
KR890005110A (ko) 신규의 3-아로일-6,7-디히드로-5h-피롤로[1,2-c]이미다졸-7-카르복시산유도체
CA2201096A1 (en) Solid dispersion and solid dispersion dosage form of xanthine derivative